Clinical trials: Renal Carcinoma
Kidney Cancer
Interferon Alfa With or Without Interleukin-2 and Fluorouracil in Treating Patients With Advanced Metastatic Kidney Cancer
RATIONALE: Interferon alfa may interfere with the growth of tumor cells. Interleukin-2 may stimulate a person's white blood cells to kill tumor cells.
- Trial name
- NCT00053820
- Testing
- aldesleukin, recombinant interferon alfa, fluorouracil
- Where
- 12 sites in Belgium, Germany and 2 more
- Volunteers
- 670 people
- Sponsor
- Medical Research Council
Hepatocellular Carcinoma, Renal Cell Carcinoma
Genome-wide Association Study to Predict Treatment Response for Molecular Targeted Therapy in Hepatocellular Carcinoma and Renal Cell Carcinoma
All Hepatocellular carcinoma and Renal cell carcinoma patients who receive molecular targeted therapy will be candidates for the study.
- Trial name
- NCT01482520
- Where
- South Korea
- Volunteers
- 200 people
- Sponsor
- Samsung Medical Center
Kidney (Renal Cell) Cancer
Impact of C-arm CT in Decreased Renal Function Undergoing TACE for Tx of Hepato-Cellular Carcinoma
Impact on contrast dose or total volume of contrast required to effectively treat the targeted tumor.
- Trial name
- NCT01326390
- Testing
- dTA/dBA C-arm fluoroscopy system with Dyna CT, DSA arteriogram- hepatic arteries, CO2 aortogram
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Stanford University
Recurrent Renal Cell Cancer, Stage I Renal Cell Cancer
Fluorescence Imaging in Finding Tumors in Patients With Kidney Tumors
RATIONALE: Using fluorescence imaging may determine the extent of kidney tumors and help in planning surgery. PURPOSE: This phase I trial is studying the best way to give indocyanine green (ICG) fluorescence imaging in finding…
- Conditions
- Recurrent Renal Cell Cancer, Stage I Renal Cell Cancer, Stage II Renal Cell Cancer
- Trial name
- NCT01281488
- Testing
- fluorescence imaging, laparoscopic surgery, indocyanine green
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- City of Hope Medical Center
Advanced Malignant Solid Neoplasm, Malignant Solid Neoplasm
Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)
This phase II Pediatric MATCH treatment trial studies how well ensartinib works in treating patients with solid tumors, non-Hodgkin lymphoma, or histiocytic disorders with ALK or ROS1 genomic alterations that have come back…
- Conditions
- Advanced Malignant Solid Neoplasm, Malignant Solid Neoplasm, Recurrent Ependymoma, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
- Trial name
- NCT03213652
- Testing
- Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Bone Scan
- Where
- 126 sites in United States, Australia and 2 more
- Volunteers
- 13 people
- Sponsor
- National Cancer Institute (NCI)
Renal Cell Carcinoma
T Regulatory Cells in Renal Cell Carcinoma (PILOT STUDY)
To define the frequency of T regulatory cells in peripheral blood of RCC patients before and after nephrectomy. Study hypothesis: That nephrectomy results in a normalisation of peripheral blood T regs in early stage RCC, and a…
- Trial name
- NCT00717743
- Where
- Singapore
- Sponsor
- National University Hospital, Singapore
Pre- and Postoperative Analgesia, Spinal Anesthesia
Randomized Study of Spinal Anesthesia Compared With Traditional Epidural Anesthesia Concerning Peroperative and Postoperative Pain After Open Nephrectomy in Patients With Renal Cell Carcinoma
The study aim to study whether spinal anesthesia (using: bupivacain, morfin och klonidin) can be better than epidural anesthesia during and after open surgery for renal cell carcinoma.
- Conditions
- Pre- and Postoperative Analgesia, Spinal Anesthesia, Renal Cell Carcinoma
- Trial name
- ASA (NCT02030717)
- Testing
- klonidin, epidural anesthesia
- Where
- Sweden
- Volunteers
- 120 people
- Sponsor
- Umeå University
Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter
Cisplatin Plus Gemcitabine With or Without Paclitaxel in Treating Patients With Stage IV Urinary Tract Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known which combination chemotherapy regimen is more effective for urinary tract cancer.
- Conditions
- Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter, Urethral Cancer
- Trial name
- NCT00022191
- Testing
- cisplatin, gemcitabine hydrochloride, paclitaxel
- Where
- 234 sites in United States, Australia and 14 more
- Volunteers
- 608 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Renal Cell Carcinoma
Moesin Expression in Clear Cell Renal Cell Carcinoma
Renal cell carcinoma (RCC) is the most frequently occurring primary renal neoplasm. There are several histological variants of RCC that are associated with variable prognostic outcomes.
- Trial name
- NCT06055660
- Testing
- Immunohistochemical detection of Moesin in Clear cell Renal Cell Carcinoma
- Volunteers
- 50 people
- Sponsor
- Sohag University
Papillary Renal Carcinoma, Variant Histology Urothelial Carcinoma
Genitourinary Tumors With Sacituzumab Tirumotecan
RINGQUEST is a Phase 2, open-label, single arm, basket, investigator-initiated clinical trial of sacituzumab tirumotecan in patients with: Cohort 1: papillary renal carcinoma (pRCC).
- Trial name
- RINGQUEST (NCT07716917)
- Testing
- Sacituzumab Tirumotecan (SKB264)
- Where
- Spain
- Volunteers
- 100 people
- Sponsor
- Alianza multidisciplinar para la investigación de los tumores genitourinarios -GUARD
Colorectal Cancer, Renal Cell Carcinoma
Study of DC-CTL Combined With CIK for Advanced Solid Tumor
Background: Combinations of Dendritic and Cytokine-induced Killer Cells (DC-CIK) and Cytokine-induced Killer Cells (CIK) treatment may enhance the immune response and stop cancer cells from growing.
- Conditions
- Colorectal Cancer, Renal Cell Carcinoma, Nasopharyngeal Carcinoma, Lung Cancer
- Trial name
- NCT03047525
- Testing
- Cytokine-induced Killer Cells
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Xiaoyi Huang
Solid Tumor Malignancies, Hematologic Cancer
The Application of 18F-G1 PET/CT Targeting Granzyme B in the Pan-cancer Immunotherapy
The purpose of this study is to explore the effectiveness of 18F-G1 PET/CT in patients with solid tumors and hematological malignancies receiving immunotherapy
- Conditions
- Solid Tumor Malignancies, Hematologic Cancer, Lung Cancer, Esophagus Cancer
- Trial name
- NCT07039474
- Testing
- 18F-G1
- Where
- China
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Peking University First Hospital
Metastatic Cancer, Recurrent Cancer
IRX-2 Regimen Combined With Nivolumab in Recurrent/Metastatic Solid Tumors
This study is to determine the safety of IRX-2 Regimen combined with Nivolumab in patients with recurrent metastatic solid tumors.
- Conditions
- Metastatic Cancer, Recurrent Cancer, Solid Tumor, Renal Cell Carcinoma
- Trial name
- NCT03758781
- Testing
- IRX 2, Nivolumab
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Renal Cell Carcinoma
Multimodal Recurrence Scoring System for Stratifying Stage III Clear Cell Renal Cell Carcinoma of Receiving Adjuvant Treatment
Whether patients with stage III clear cell renal cell carcinoma (ccRCC) should receive adjuvant targeted therapy or not is still on debate.
- Trial name
- NCT06032728
- Testing
- Sunitinib
- Volunteers
- 488 people
- Sponsor
- First Affiliated Hospital, Sun Yat-Sen University
Clear Cell Renal Cell Carcinoma, Locally Advanced Clear Cell Renal Cell Carcinoma
Testing AZD1775 in Advanced Solid Tumors That Have a Mutation Called SETD2
This phase II trial studies how well adavosertib works in treating patients with SETD2-deficient solid tumors that have spread to other places in the body (advanced/metastatic).
- Conditions
- Clear Cell Renal Cell Carcinoma, Locally Advanced Clear Cell Renal Cell Carcinoma, Locally Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm
- Trial name
- NCT03284385
- Testing
- Adavosertib
- Where
- 29 sites in United States
- Volunteers
- 18 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Renal Cancer
Everolimus Modulation of Anti-tumor T CD4 Immune Responses
Everolimus is an inhibitor of mammalian target of rapamycin, approved in patients with metastatic renal cell carcinoma. The objective of this study is to investigated the influence of everolimus immune modulation on antitumor…
- Trial name
- EMIR (NCT02837757)
- Testing
- Biological samples
- Where
- 3 sites in France
- Volunteers
- 14 people
- Sponsor
- Centre Hospitalier Universitaire de Besancon
Renal Cell Carcinoma
Correlation of the Clinical Behaviour of Renal Cell Carcinoma (RCC) After Debulking Nephrectomy With Tumor Gene Expression in Nephrectomy Specimens
The objective of the study is to determine whether a specific immune microenvironment in the primary tumor is associated with a favorable clinical course after nephrectomy and in the absence of adjuvant treatment.
- Trial name
- NCT00718367
- Where
- Singapore
- Sponsor
- National University Hospital, Singapore
Colorectal Carcinoma, Renal Cancer
Irreversible Electroporation (IRE) for Treating Recurrent Pelvic Tumors (PELFIRE Study)
The goal of this single-center observational cohort study, based on a registry combining retrospectively and prospectively collected data, is to investigate the short- and long-term effects of irreversible electroporation (IRE)…
- Conditions
- Colorectal Carcinoma, Renal Cancer, Bladder Cancer, Cervical Cancer
- Trial name
- PELFIRE (NCT07782164)
- Testing
- Irreversible electroporation
- Where
- Netherlands
- Volunteers
- 27 people
- Sponsor
- Amsterdam UMC, location VUmc
Resectable Clear Cell Carcinoma of the Kidney
Cardenilimab Combined With Lenvatinib in Patients With Perioperative Resectable Clear Cell Renal Cell Carcinoma.
This study is a single-arm, single-center, phase II clinical study. The main purpose is to evaluate the perioperative efficacy and safety of cardenilimab combined with lenvatinib in patients with resectable clear cell renal cell…
- Trial name
- NCT06574412
- Testing
- cardonilizumab combined with renvastinib
- Volunteers
- 30 people
- Sponsor
- The First Hospital of Jilin University
Advanced Cancer
Phase 1/1b Study of MGCD516 in Patients With Advanced Cancer
MGCD516 is a receptor tyrosine kinase (RTK) inhibitor shown in preclinical models to inhibit a closely related spectrum of RTKs including MET, AXL, MER, and members of the VEGFR, PDGFR, DDR2, TRK and Eph families.
- Trial name
- NCT02219711
- Testing
- MGCD516
- Where
- 43 sites in United States, South Korea
- Volunteers
- 193 people
- Sponsor
- Mirati Therapeutics Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.